1

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 2 of 15

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-68. (Canceled).

69. (Currently amended) A method of treating, or preventing, or delaying progression of prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen (PSMA) with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, or prevent, or delay the progression of prostate cancer.

- 70. (Currently amended) The method according to claim 69, wherein the prostate cancer is metastatic <u>prostate</u> cancer.
- 71. (Previously presented) The method according to claim 70, wherein the metastatic prostate cancer involves a bone marrow or a lymph node metastasis.
- 72. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the administering is carried out parenterally.
- 73. (Currently amended) [[A]] <u>The</u> method according to claim [[72]] <u>69</u>, wherein the administering is carried out intravenously.

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 3 of 15

74. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the administering is carried out by intracavitary instillation.

- 75. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the administering is carried out rectally.
- 76. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion thereof is administered following a prostatectomy.
- 77. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion binds live cells.
- 78. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.
- 79. (Currently amended) [[A]] <u>The</u> method according to claim 78, wherein the antibody is <u>a monoclonal antibody</u> selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.
- 80. (Currently amended) [[A]] <u>The</u> method according to claim 78, wherein the antibody is a monoclonal antibody produced by a hybridoma having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

81-123. (Canceled)

124. (Currently amended) A method of treating, or preventing or delaying progression of prostate cancer comprising:

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 4 of 15

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is labeled with the radiolabel ⁹⁰Y; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat or prevent or delay the progression of prostate cancer.

125. (Currently amended) A method of treating, or preventing, or delaying progression of prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is labeled with a radiolabel, and wherein the radiolabel is a beta- or gamma-emitter; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, or prevent or delay the progression of prostate cancer.

126. (Currently amended) A method of treating, or preventing, or delaying progression of prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is bound to a cytotoxic drug of bacterial origin; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, or prevent, or delay the progression of prostate cancer.

127. (Currently amended) A method of treating, or preventing or delaying progression of prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to

Attorney's Docket No.: 10448-184002 / MPI96-

037P2RDV1A(RCE)

Applicant: Neil H. Bander Serial No.: 09/357,704 Filed: July 20, 1999

Page : 5 of 15

prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is bound to a cytotoxic drug of plant origin; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, or prevent or delay the progression of prostate cancer.

128. (Canceled)

- 129. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with <u>the J591</u> monoclonal antibody [[J591]].
- 130. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with <u>the J415</u> monoclonal antibody [[J415]].

131.-135. (Canceled).

- 136. (Currently amended) [[A]] <u>The</u> method according to claim 69, 125, 126 or 127, wherein the antibody is a monoclonal antibody <u>or the antigen binding portion thereof is derived from a monoclonal antibody</u>.
- 137. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is internalized with the prostate specific membrane antigen.
- 138. (Currently amended) [[A]] <u>The</u> method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is selected from the group consisting of

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 6 of 15

a Fab fragment, a [[F(ab')2]] F(ab')2 fragment, and a Fv fragment.

- 139. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion thereof further comprises a cytotoxic drug.
- 140. (Currently amended) [[A]] <u>The</u> method according to claim 139, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation, <u>a molecule</u> molecules of plant, fungal, or bacterial origin, <u>a</u> biological <u>protein</u> proteins, and a mixture mixtures thereof.
- 141. (Currently amended) [[A]] <u>The</u> method according to claim 140, wherein the cytotoxic drug is a compound emitting radiation.
- 142. (Currently amended) [[A]] <u>The</u> method according to claim 141, wherein the compound emitting radiation is an alpha-emitter.
- 143. (Currently amended) [[A]] <u>The</u> method according to claim 142, wherein the alphaemitter is selected from the group consisting of ²¹²Bi, ²¹³Bi, and ²¹¹At.
- 144. (Currently amended) [[A]] <u>The</u> method according to claim 141, wherein the compound emitting radiation is a beta-emitter.
- 145. (Currently amended) [[A]] <u>The</u> method according to claim 144, wherein the beta-emitter is ¹⁸⁶Re.
- 146. (Currently amended) [[A]] <u>The</u> method according to claim 144, wherein the betaemitter is ⁹⁰Y.

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 7 of 15

147. (Currently amended) [[A]] <u>The</u> method according to claim 141, wherein the compound emitting radiation is a gamma-emitter.

- 148. (Currently amended) [[A]] <u>The</u> method according to claim 147, wherein the gamma-emitter is ¹³¹I.
- 149. (Currently amended) [[A]] <u>The</u> method according to claim 141, wherein the compound emitting radiation is a beta- and gamma-emitter.
- 150. (Currently amended) [[A]] <u>The</u> method according to claim 140, wherein the cytotoxic drug is a molecule of bacterial origin.
- 151. (Currently amended) [[A]] The method according to claim 140, wherein the cytotoxic drug is a molecule of plant origin.
- 152. (Currently amended) [[A]] <u>The</u> method according to claim 140, wherein the cytotoxic drug is a biological protein.
- 153. (Currently amended) [[A]] <u>The</u> method according to claim 69, wherein the antibody or antigen binding portion thereof further comprises a label.
- 154. (Currently amended) [[A]] <u>The</u> method according to claim 153, wherein the label is selected from the group consisting of a biologically-active enzyme label[[,]] and a radiolabel.
- 155. (Currently amended) [[A]] <u>The</u> method according to claim 154, wherein the label is a radiolabel selected from the group consisting of ¹¹¹In, [[⁹⁹mTc]] ^{99m}Tc, ³²P, ¹²⁵I, ¹³¹I, ¹⁴C, ³H and ¹⁸⁸Rh.

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 8 of 15

156. (Currently amended) [[A]] <u>The</u> method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is effective to initiate an endogenous host immune function.

- 157. (Currently amended) [[A]] <u>The</u> method according to claim 156, wherein the endogenous host immune function is complement-mediated cellular cytotoxicity.
- 158. (Currently amended) [[A]] <u>The</u> method according to claim 156, wherein the endogenous host immune function is antibody-dependent cellular cytotoxicity.
- 159. (Currently amended) [[A]] <u>The</u> method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is in a composition further comprising a pharmaceutically acceptable carrier, excipient, or stabilizer.
- 160. (Previously presented) The method according to claim 69, 125, 126 or 127 wherein the antibody or antigen binding portion thereof is administered in conjunction with a second therapeutic modality.
- 161. (Previously presented) The method according to claim 160, wherein the second therapeutic modality is selected from the group consisting of surgery, radiation, chemotherapy, immunotherapy and hormone replacement.
- 162. (Previously presented) The method according to claim 161, wherein the hormone replacement comprises treatment with estrogen or an anti-androgen agent.
- 163. (Previously presented) The method according to claim 162, wherein the antiandrogen agent is an agent which blocks or inhibits the effects of testosterone.

Serial No.: 09/357,704 Filed: July 20, 1999

Page : 9 of 15

164. (Currently amended) The method according to claim 126, wherein the prostate cancer is metastatic prostate cancer.

- 165. (Previously presented) The method according to claim 164, wherein the metastatic prostate cancer involves a bone marrow or a lymph node metastasis.
- 166. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the administering is carried out parenterally.
- 167. (Currently amended) [[A]] <u>The</u> method according to claim [[166]] <u>126</u>, wherein the administering is carried out intravenously.
- 168. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the administering is carried out by intracavitary instillation.
- 169. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the administering is carried out rectally.
- 170. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the antibody or antigen binding portion thereof is administered following a prostatectomy.
- 171. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the antibody or antigen binding portion binds live cells.
- 172. (Currently amended) [[A]] <u>The</u> method according to claim 126, wherein the antibody is <u>a monoclonal antibody</u> selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

Attorney's Docket No.: 10448-184002 / MPI96-

Applicant: Neil H. Bander 037P2RDV1A(RCE) Serial No.: 09/357,704

: July 20, 1999 Page : 10 of 15

173. (Currently amended) [[A]] The method according to claim 126, wherein the antibody is a monoclonal antibody produced by a hybridoma having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

174 -185. (Canceled)

186. (Currently amended) [[A]] The method according to claim 126, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with the J591 monoclonal antibody [[J591]].

187-189. (Canceled)

190. (New) The method according to claim 69, 124, 125, 126, or 127, wherein the method of treating prostate cancer is a method that prevents or delays the progression of prostate cancer.